![]() Want to know more about Kite? Read: How Kite Pharma Is Revolutionizing the Fight Against Cancer and listen to the podcast below. Kite is currently a Zacks Rank #3 (Hold). View historical data and performance charts. Shares of Kite skyrocketed from $45.95 a share in early January to $179.69 per share on Monday. Information about Kite Pharma share price and performance, this page displays NASDAQ: KITE stock exchange data. Gilead stock is currently a Zacks Rank #2 (Buy) and scored an "A" for Value in our Style Score system. Kite's cancer therapy drug could eventually go beyond the treatment of lymphoma to other forms of blood cancers.Īccording to some analysts, Kite's axi-cel sales could reach $1.7 billion by 2022, which would rank the drug within the top 10 in the industry in terms of sales potential. Gilead grew into a $100 billion biotech company by selling treatments for HIV/AIDS and hepatitis C. Food and Drug Administration, and the FDA's target action date is November 29, with European approval set for next year. The Axi-cel treatment is currently under review by the U.S. The company expects axi-cel to be approved as a treatment to fight aggressive non-Hodgkin lymphoma. Kite's biggest, most advanced offering is a CAR T therapy called axicabtagene ciloleucel, or axi-cel. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer." "The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. "The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers," Gilead President and CEO John F. However, the Kite acquisition won't become neutral in terms of earnings until the third year of the deal, according to Gilead. ![]() Gilead made it clear in its official announcement that the Kite purchase is designed to diversify its drug offerings. Shares of Kite reached a new all-time high on Monday, and the company's shares have already traded hands more than eight times its average volume. Kite and Gilead's board of directors both unanimously approved the deal, which will reportedly close in the fourth quarter. This reading ranks in the 95th percentile of its annual range, pointing toward a very unusual put-skew among options that expire in three months or less.Gilead's $180 a share purchase marks a 29% premium from Kite's Friday close. Some options traders may have been betting against the possibility of a buyout, based on TRCO's Schaeffer's put/call open interest ratio (SOIR) of 1.25. Tribune Media Co had been gaining on the charts due to the M&A chatter, and today's move puts its 2017 advance at 44.5%. ![]() TRCO stock earlier hit an annual high of $43.04, and was last seen up 5.3% at $42.43, after Sinclair Broadcast Group Inc (NASDAQ:SBGI) said it planned to buy Tribune Media in a cash-and-stock deal worth $3.9 billion - or $43.50 per share. Sinclair Buyout Sends Tribune Media to New High Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) reveals a 10-day call/put volume ratio of 5.47 for Gigamon Inc, which ranks in the 78th annual percentile. Options traders are likely cheering today's price action, though. 18, but remain below their year-to-date breakeven point of $45.55. The shares are set for their highest close since Jan. GIMO stock is one of the top gainers on the New York Stock Exchange, adding 17.7% to trade at $41.20, thanks to news hedge fund Elliott Management has taken a roughly 15% stake in the company. Analysts certainly have high expectations for Kite Pharma Inc, with 10 of the 14 covering brokerage firms rating the stock a "buy" or "strong buy." Gigamon Stock Soars on Elliott Management Stake Still, the shares earlier found a floor at their rising 80-day moving average, and still sport a roughly 62% year-to-date lead. KITE stock has landed on the short-sale restricted list today, down 11.2% at $72.60, due to disappointing first-quarter results, and news that a patient died in its lead CAR-T therapy study. Here's a quick look at what's moving shares of KITE, GIMO, and TRCO. Among specific stocks on the move are drug stock Kite Pharma Inc (NASDAQ:KITE), tech issue Gigamon Inc (NYSE:GIMO), and media concern Tribune Media Co (NYSE:TRCO). ![]() stocks are struggling to hold gains this afternoon.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |